TherapywithDMARDsshouldbestartedassoonasthediagnosisofRAismade.
一旦诊断,即应尽快开始DMARDs治疗。
02Treatmentshouldbeaimedatreachingatargetofsustained
remmissionorlowdiseaseactivityineverypatient.
以持续缓解或低疾病活动度作为目标。
03Monitoringshouldbefrequentinactivedisease（every1-3months）；ifthereisnoimprovementbyatmost3monthsafterthestartoftreatmentorthetargethasnotbeenreachedby6months,therapyshouldbeadjusted.
密切监测病情（每1-3个月）；调整治疗方案（3个月无改善或6个月不达标）。
04MTXshouldbepartofthefirsttreatmentstrategy.
MTX作为最初的用药。
05InpatientswithacontraindicationtoMTX（orearlyintolerance），leflunomideorsulfasalazineshouldbeconsideredaspartofthe（first）treatmentstrategy.
对MTX有禁忌或早期不耐受，可考虑LEF或SASP。
06ShorttermglucocorticoidsshouldbeconsideredwheninitiatingorchangingcsDMARDs,indifferentdoseregimentsandroutesofadministration,butshouldbetaperedasrapidlyasclinicallyfeasible.
在起始和更换csDMARDs时，可考虑短期糖皮质激素治疗，但应尽快减量。
07IfthetreatmenttargetisnotachievedwiththefirstcsDMARDstrategy,intheabsenceofpoorprognosticfactors,otherDMARDsshouldbeconsidered.
初始csDMARD治疗疗效不佳时，无预后不良因素，可更换其他DMARDs。
08IfthetreatmenttargetisnotachievedwiththefirstcsDMARDstrategy,whenpoorprognosticfactorsarepresent,additionofabDMARDortsDMARDshouldbeconsidered;currentpracticewouldbetostartabDMARD.
csDMARD治疗未达标，有预后不良因素，可考虑加用bDMARD和tsDMARD。
09